AI-developed drug will be in trials by year-end, says Google’s Hassabis
Isomorphic was spun out of Google’s AI research arm Google DeepMind in 2021, but remains a wholly owned subsidiary of its parent company, Alphabet. The start-up’s potential has attracted big pharmaceutical partners, which are keen to lower expenses and boost efficiency of the costly drug development process.
Jayqwan Hamilton, 37, Robert DeMaio, 36, and Jacob Barroso, 32 -- shuffled into a Manhattan courtroom for the first day of a ...
Three men have been accused of murder as part of a plot to drug and rob revelers in Midtown in 2022. Two of their targets ...
Trump rescinded Executive Order 14087, "Lowering Prescription Drug Costs for Americans," which directed Medicare and Medicaid ...
A new study by researchers from the Brown University School of Public Health found that pregnant women are regularly excluded ...
The IRA’s price controls discourage post-marketing research. The potential benefits from expanding access to the drug to ...
An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end.
The blood–brain barrier is the biggest challenge to the development of drugs that target the CNS. Most capillary beds leak plasma contents between and across endothelial cells by way of window-like ...
Some antibiotics, antivirals, vaccinations and anti-inflammatory medications are linked to a reduced risk of dementia, a ...
Google DeepMind spinoff Isomorphic Labs expects testing on its first AI-designed drugs to begin this year, as tech startups ...
Two new studies have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials against breast cancer.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback